SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK, Libor USTOHAL, Josef TOMANDL, Lubomír VOJTÍŠEK, Petr KUDLIČKA, Martin JÁNI, T. Wilson WOO, Tomáš KAŠPÁREK, Zora KIKINIS a Marek KUBICKI. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study. Neuropsychopharmacology. London: Springer-Nature, 2022, roč. 47, č. 2, s. 524-530. ISSN 0893-133X. Dostupné z: https://dx.doi.org/10.1038/s41386-021-00997-5.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study
Autoři SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK (203 Česká republika, domácí), Libor USTOHAL (203 Česká republika, domácí), Josef TOMANDL (203 Česká republika, domácí), Lubomír VOJTÍŠEK (203 Česká republika, domácí), Petr KUDLIČKA (203 Česká republika, domácí), Martin JÁNI (703 Slovensko, domácí), T. Wilson WOO, Tomáš KAŠPÁREK (203 Česká republika, domácí), Zora KIKINIS a Marek KUBICKI.
Vydání Neuropsychopharmacology, London, Springer-Nature, 2022, 0893-133X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30215 Psychiatry
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 7.600
Kód RIV RIV/00216224:14110/22:00124919
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1038/s41386-021-00997-5
UT WoS 000638047300004
Klíčová slova anglicky matrix metalloproteinase 9 (MMP9); hippocampal volume; schizophrenia
Štítky 14110127, 14110222, 14110512, CF MAFIL, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 1. 2. 2022 11:27.
Anotace
Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.
Návaznosti
LM2018129, projekt VaVNázev: Národní infrastruktura pro biologické a medicínské zobrazování Czech-BioImaging
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, National research infrastructure for biological and medical imaging
VytisknoutZobrazeno: 12. 5. 2024 07:18